Kristen Kluska
Stock Analyst at Cantor Fitzgerald
(4.42)
# 304
Out of 5,067 analysts
232
Total ratings
44.76%
Success rate
27.99%
Average return
Main Sectors:
Stocks Rated by Kristen Kluska
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LXEO Lexeo Therapeutics | Initiates: Overweight | $19 | $9.99 | +90.19% | 1 | Nov 20, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Overweight | $29 → $24 | $8.65 | +177.46% | 4 | Nov 6, 2025 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $32 → $38 | $49.80 | -23.69% | 9 | Nov 5, 2025 | |
| IRON Disc Medicine | Maintains: Overweight | $132 → $153 | $94.11 | +62.58% | 9 | Oct 17, 2025 | |
| SUPN Supernus Pharmaceuticals | Maintains: Overweight | $46 → $63 | $45.15 | +39.53% | 4 | Sep 30, 2025 | |
| QURE uniQure | Maintains: Overweight | $47 → $80 | $27.78 | +187.98% | 10 | Sep 25, 2025 | |
| RARE Ultragenyx Pharmaceutical | Reiterates: Overweight | $105 | $32.78 | +220.32% | 20 | Sep 5, 2025 | |
| PTCT PTC Therapeutics | Reiterates: Overweight | $118 | $79.83 | +47.81% | 21 | Sep 3, 2025 | |
| MNPR Monopar Therapeutics | Reiterates: Overweight | $74 | $92.57 | -20.06% | 2 | Aug 27, 2025 | |
| EPRX Eupraxia Pharmaceuticals | Initiates: Overweight | $11 | $6.20 | +77.42% | 1 | Jul 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $16 | $4.91 | +225.87% | 1 | May 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $10 | $11.74 | -14.82% | 4 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $30 | $4.64 | +546.55% | 6 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $163 → $81 | $18.91 | +328.34% | 16 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 | $4.42 | +58.37% | 16 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $67 → $123 | $45.91 | +167.92% | 6 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $90 | $3.80 | +2,268.42% | 4 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 | $1.79 | +291.06% | 10 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $18.32 | +36.46% | 9 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $67 | $26.36 | +154.17% | 15 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $9.89 | +112.34% | 7 | Jan 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $17 | $5.78 | +194.12% | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $8 | $3.17 | +152.37% | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $11 | $1.59 | +591.82% | 6 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $18 | $4.59 | +292.16% | 8 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $14 | $1.30 | +976.92% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $13 | $1.28 | +915.63% | 7 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $1.37 | +1,432.85% | 3 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $1.75 | +242.86% | 3 | Feb 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $90 → $20 | $1.80 | +1,011.11% | 2 | Aug 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $23 | $3.65 | +530.14% | 2 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $900 | $1.18 | +76,171.19% | 1 | Aug 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $400 | $16.31 | +2,352.48% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1,250 → $85 | $1.11 | +7,557.66% | 3 | Oct 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $6.55 | +2,648.09% | 1 | Dec 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $2.38 | +7,463.03% | 1 | May 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $11 | $1.19 | +824.37% | 3 | May 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $1.13 | +5,209.73% | 2 | Mar 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $90 | $1.15 | +7,726.09% | 1 | Dec 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $10,620 → $2,520 | $0.83 | +302,348.39% | 2 | Jan 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $160 | $0.29 | +55,320.85% | 1 | Jan 9, 2020 |
Lexeo Therapeutics
Nov 20, 2025
Initiates: Overweight
Price Target: $19
Current: $9.99
Upside: +90.19%
Zevra Therapeutics
Nov 6, 2025
Maintains: Overweight
Price Target: $29 → $24
Current: $8.65
Upside: +177.46%
Rigel Pharmaceuticals
Nov 5, 2025
Maintains: Neutral
Price Target: $32 → $38
Current: $49.80
Upside: -23.69%
Disc Medicine
Oct 17, 2025
Maintains: Overweight
Price Target: $132 → $153
Current: $94.11
Upside: +62.58%
Supernus Pharmaceuticals
Sep 30, 2025
Maintains: Overweight
Price Target: $46 → $63
Current: $45.15
Upside: +39.53%
uniQure
Sep 25, 2025
Maintains: Overweight
Price Target: $47 → $80
Current: $27.78
Upside: +187.98%
Ultragenyx Pharmaceutical
Sep 5, 2025
Reiterates: Overweight
Price Target: $105
Current: $32.78
Upside: +220.32%
PTC Therapeutics
Sep 3, 2025
Reiterates: Overweight
Price Target: $118
Current: $79.83
Upside: +47.81%
Monopar Therapeutics
Aug 27, 2025
Reiterates: Overweight
Price Target: $74
Current: $92.57
Upside: -20.06%
Eupraxia Pharmaceuticals
Jul 24, 2025
Initiates: Overweight
Price Target: $11
Current: $6.20
Upside: +77.42%
May 22, 2025
Assumes: Overweight
Price Target: $16
Current: $4.91
Upside: +225.87%
May 15, 2025
Upgrades: Overweight
Price Target: $10
Current: $11.74
Upside: -14.82%
May 14, 2025
Reiterates: Overweight
Price Target: $30
Current: $4.64
Upside: +546.55%
May 7, 2025
Maintains: Overweight
Price Target: $163 → $81
Current: $18.91
Upside: +328.34%
Apr 28, 2025
Reiterates: Overweight
Price Target: $7
Current: $4.42
Upside: +58.37%
Mar 27, 2025
Maintains: Overweight
Price Target: $67 → $123
Current: $45.91
Upside: +167.92%
Mar 26, 2025
Reiterates: Overweight
Price Target: $90
Current: $3.80
Upside: +2,268.42%
Mar 18, 2025
Reiterates: Overweight
Price Target: $7
Current: $1.79
Upside: +291.06%
Mar 4, 2025
Reiterates: Overweight
Price Target: $25
Current: $18.32
Upside: +36.46%
Jan 29, 2025
Reiterates: Overweight
Price Target: $67
Current: $26.36
Upside: +154.17%
Jan 15, 2025
Reiterates: Overweight
Price Target: $21
Current: $9.89
Upside: +112.34%
Dec 17, 2024
Initiates: Overweight
Price Target: $17
Current: $5.78
Upside: +194.12%
Dec 17, 2024
Initiates: Overweight
Price Target: $8
Current: $3.17
Upside: +152.37%
Nov 22, 2024
Reiterates: Overweight
Price Target: $11
Current: $1.59
Upside: +591.82%
Oct 29, 2024
Reiterates: Overweight
Price Target: $18
Current: $4.59
Upside: +292.16%
Sep 20, 2024
Reiterates: Overweight
Price Target: $14
Current: $1.30
Upside: +976.92%
Sep 20, 2024
Reiterates: Overweight
Price Target: $13
Current: $1.28
Upside: +915.63%
Apr 30, 2024
Reiterates: Overweight
Price Target: $21
Current: $1.37
Upside: +1,432.85%
Feb 5, 2024
Reiterates: Overweight
Price Target: $6
Current: $1.75
Upside: +242.86%
Aug 30, 2023
Downgrades: Neutral
Price Target: $90 → $20
Current: $1.80
Upside: +1,011.11%
Aug 29, 2023
Reiterates: Overweight
Price Target: $23
Current: $3.65
Upside: +530.14%
Aug 24, 2023
Reiterates: Overweight
Price Target: $900
Current: $1.18
Upside: +76,171.19%
Mar 17, 2023
Initiates: Overweight
Price Target: $400
Current: $16.31
Upside: +2,352.48%
Oct 7, 2022
Downgrades: Neutral
Price Target: $1,250 → $85
Current: $1.11
Upside: +7,557.66%
Dec 29, 2021
Initiates: Overweight
Price Target: $180
Current: $6.55
Upside: +2,648.09%
May 26, 2021
Initiates: Overweight
Price Target: $180
Current: $2.38
Upside: +7,463.03%
May 7, 2021
Downgrades: Neutral
Price Target: $15 → $11
Current: $1.19
Upside: +824.37%
Mar 19, 2021
Initiates: Overweight
Price Target: $60
Current: $1.13
Upside: +5,209.73%
Dec 1, 2020
Initiates: Overweight
Price Target: $90
Current: $1.15
Upside: +7,726.09%
Jan 30, 2020
Assumes: Overweight
Price Target: $10,620 → $2,520
Current: $0.83
Upside: +302,348.39%
Jan 9, 2020
Initiates: Overweight
Price Target: $160
Current: $0.29
Upside: +55,320.85%